Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ALG-010133 in Healthy Volunteers and Chronic Hepatitis B
NCT04485663Phase 1Terminated
- Sponsor
- Aligos Therapeutics
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Antisense DNA, RNA Aptamers, Modified DNA Aptamers
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ALG-010133 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 162 days. Started Aug 2020; status: terminated.
02
Drugs
ALG-010133
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04485663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485663.